Cobicistat Tablet shortage
Cobicistat Tablet is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 17, 2026.
Gilead is stopping cobicistat 150 mg tablets, and this change is expected to be permanent. No other manufacturer of this medicine is listed, so it will not be available after Gilead sells through its remaining supply by the end of February 2026.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Cobicistat Tablet. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Oct 7, 2025Currently in shortage1 of 1 product affected.
-
Oct 7, 2025First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Gilead Sciences, Inc. 📞 800-445-3235 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Tybost, Tablet, 150 mg (NDC 61958-1401-1) | — | — | Gilead plans to sell through the end of February 2026. Discontinuation of the manufacture of the drug due to business reasons. | — |
These rows are manufacturer reports to the FDA for Cobicistat Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Cobicistat Tablet? options further down this page.
Why is Cobicistat Tablet in shortage?
Gilead Sciences has decided to permanently stop making Tybost (cobicistat) 150 mg tablets for business reasons — meaning this is a company business decision rather than a manufacturing problem or safety concern. This affects the specific 150 mg tablet package listed under Gilead's name (NDC 61958-1401-1).
According to Gilead, they plan to continue selling their remaining supply through the end of February 2026, so the product won't disappear overnight. After that point, Gilead will no longer be supplying this particular product. No additional public explanation beyond "business reasons" was shared by the manufacturer.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Cobicistat Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Cobicistat Tablet?
Cobicistat (brand name Tybost) 150 mg tablets are currently on the FDA shortage list, and the status is listed as "to be discontinued."
The only strength involved is the 150 mg tablet, and right now no available source is reported for it. The manufacturer, Gilead Sciences, has stated it plans to sell through the end of February 2026 and is stopping production for business reasons. Because this is a planned discontinuation rather than a temporary supply gap, this change may be permanent. That makes a conversation with your prescriber the right next step so you can plan ahead.
Please keep this in mind, in order:
- Do not stop, skip, or change your dose on your own — keep taking it as prescribed.
- While supply lasts, ask your pharmacy to order the 150 mg tablet; pharmacies can check wholesalers and other sources.
- Because this medicine is being discontinued, talk with your prescriber or pharmacist soon about a planned, clinician-chosen path forward.
- The manufacturer's contact number is listed on this page for reference, though pharmacies usually handle those calls.
This information comes from national, manufacturer-reported FDA data and may not match your local pharmacy's actual stock. It is general information, not individual medical advice.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Therapeutic equivalents & pricing 1 productclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Tybost 150 mg | Gilead | 30 tablets | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Identity & classification
Where does this data come from?
Other antiviral shortages
Cobicistat Tablet shortage FAQs
Is Cobicistat Tablet in shortage?
Which products are affected?
When will Cobicistat Tablet be available again?
What should I do if I take Cobicistat Tablet?
Still have a question about the Cobicistat Tablet shortage?
Ask a pharmacist about this shortage →View Cobicistat Tablet on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.